Skip to content
Yog Pharma
Pain and inflammationCOX-2 selective NSAID

Celecoxib is a COX-2 selective NSAID indicated for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain and primary dysmenorrhea. We supply it to US manufacturers of capsules.

CAS169590-42-5381.4 g/molC17H14F3N3O2S
2D structure of Celecoxib.

Data from PubChem (CID 2662) and FDA’s substance registry

CAS number

169590-42-5

Molecular formula

C17H14F3N3O2S

Molecular weight

381.4g/mol

FDA UNII

IUPAC name

4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide

InChIKey

RZEKVGVHFLEQIL-UHFFFAOYSA-N

Appearance
White or almost white crystalline powder.
Solubility
Practically insoluble in water. Freely soluble in ethanol and soluble in methylene chloride.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Particle size drives dissolution, so state the distribution you developed with.

On the US market

Reference product
CelebrexNDA 020998
Approved ANDAs
18 with a marketed product
Approved forms and strengths
  • Capsule 50 mg, 100 mg, 200 mg, 400 mg
  • Oral suspension 10 mg/mL
  • Oral solution 25 mg/mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com